Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug.

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

TD Cowen also adjusted its price target for Regeneron to $1,030, lowering revenue estimates for the Eylea franchise due to increased market competition. Leerink Partners reduced its price target ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.

Regeneron Pharmaceuticals has a 1 year low of $615.00 and a 1 year high of $1,211.20. The company has a market capitalization of $67.45 billion, a PE ratio of 16.12, a price-to-earnings-growth ...

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Over the last few years, Regeneron’s ROIC has ...